Courtney Marabella

Senior Editor, OncLive®
Courtney Marabella joined the MJH Life Sciences team in 2021 and is Senior Editor for OncLive®. Prior to joining the company she worked as the Audience Development Editor for the Asbury Park Press, part of the USA Today Network. Email: cmarabella@onclive.com

Articles

Frontline Sintilimab Plus Gemcitabine/Platinum Prolongs PFS in Squamous NSCLC

June 18th 2021

The addition of sintilimab to standard chemotherapy comprised of gemcitabine and platinum significantly improved progression-free survival with acceptable safety in previously untreated patients with advanced or metastatic squamous non–small cell lung cancer.

Isatuximab Displays Promise in Early-Relapsed Multiple Myeloma, as Researchers Eye CAR T-Cell Therapy

June 17th 2021

Faith E. Davies, MD, discusses the how to approach patients with high-risk myeloma, as well as how isatuximab and CAR T-cell therapies fit best for that patient population.

ADAURA, Explosion of Targeted Agents Underscore Need for Molecular Testing in Lung Cancer

June 15th 2021

The data from the phase 3 ADAURA trial with adjuvant osimertinib are among the most significant to read out in the past year in the realm of non–small cell lung cancer.

Hillmen Highlights Acalabrutinib’s Tolerability Vs Ibrutinib in Previously Treated CLL

June 12th 2021

The next-generation, selective BTK inhibitor acalabrutinib demonstrated noninferiority to ibrutinib in terms of progression-free survival in patients with previously treated chronic lymphocytic leukemia in the phase 3 ELEVATE-RR trial.

Shah Spotlights the Potential Benefit of Brexucabtagene Autoleucel in Relapsed/Refractory B-Cell ALL, and Beyond

June 11th 2021

Bijal Shah, MD, MS, discusses the key findings of the ZUMA-3 trial, as well as key safety information regarding brexucabtagene autoleucel as a treatment for patients with heavily pretreated patients with relapsed/refractory B-cell ALL.

Real-World Analysis on Second-Line Cetuximab in mCRC Reveals Factors Linked With Longer Time on Treatment, OS

June 9th 2021

In patients with metastatic colorectal cancer who received cetuximab as a second-line therapy after irinotecan or oxaliplatin-based regimens have failed, KRAS mutational status and geographical region were associated with time on treatment, while body mass index and age were linked with overall survival.

Maintenance Olaparib/Bevacizumab Provides Substantial PFS, PFS2 Benefit in HRD+ Ovarian Cancer, Irrespective of Disease Stage

June 8th 2021

The addition of olaparib to bevacizumab provided a substantial progression-free survival (PFS) and second PFS benefit over bevacizumab alone in the maintenance treatment of patients with homologous recombination deficiency–positive, newly diagnosed advanced ovarian cancer, regardless of International Federation of Gynecology and Obstetrics disease stage.

Prolonged Treatment With Bevacizumab Does Not Yield Further Survival Benefit in Ovarian Cancer

June 7th 2021

Although prolonged treatment with bevacizumab for up to 30 months is feasible with consistent safety data for patients with primary epithelial ovarian, fallopian tube, or peritoneal cancer, the regimen did not improve survival over the standard 15 month treatment regimen.

Ultralow Risk 70-Gene Signature Is Indicative of Excellent Survival Outcomes in Early-Stage Breast Cancer

June 6th 2021

Patients with early-stage breast cancer who have ultralow risk disease indicated by a 70-gene signature demonstrated have an excellent survival prognosis regardless of clinical risk.

Single Agent and Combination TG-1701 Yield Promising Clinical Activity in CLL and Other B-Cell Malignancies

June 5th 2021

TG-1701 demonstrated encouraging clinical and pharmacodynamic activity at all dose levels in patients with B-cell malignancies.

Brexucabtagene Autoleucel Induces High, Durable Responses in Heavily Pretreated Relapsed/Refractory B-ALL

June 5th 2021

A single infusion of brexucabtagene autoleucel, a CAR T-cell therapy, demonstrated robust and durable responses in heavily pretreated patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Olaparib Provides Meaningful Benefit 1 Year After Standard of Care Therapies in BRCA1/2+, High-Risk, Early HER2- Breast Cancer

June 3rd 2021

Olaparib demonstrated clinically meaningful benefit 1 year after standard of care therapies, such as surgery, chemotherapy, hormone therapy, or radiation therapy, in patients with BRCA1/2-mutant, early HER2-negative breast cancer who are at a high risk for recurrence.

Key to Leveraging Emerging Approaches in Lung Cancer Lies in Balancing Benefit With Risk

May 28th 2021

Novel immunotherapy combinations are gaining ground in the frontline treatment of patients with lung cancer, but the toxicities associated with these regimens must be weighed against the benefit they provide.

Neoadjuvant Nivolumab/Ipilimumab Enhances Pathologic Responses in Resectable NSCLC

May 26th 2021

The addition of neoadjuvant ipilimumab to nivolumab resulted in higher rates of major pathologic response and pathologic complete response, while enhancing tumor immune cell infiltrates in patients with resectable non–small cell lung cancer, according to data from the phase 2 NEOSTAR trial.

Research Efforts Examining Novel Radiation Approaches Flourish at Fox Chase Cancer Center

May 21st 2021

Eric M. Horwitz, MD, FABS, FASTRO, and Stephanie E. Weiss, MD, FASTRO, highlight ongoing research efforts with radiation therapy that are generating excitement at their institution.

Incorporation of Brentuximab Vedotin Into Frontline Pediatric High-Risk Hodgkin Lymphoma Treatment Yields Favorable Outcomes

May 21st 2021

The integration of the anti-CD30 antibody-drug conjugate brentuximab vedotin into the frontline treatment of pediatric patients with high-risk Hodgkin lymphoma resulted in favorable clinical outcomes with promising tolerability and a reduction in radiation exposure, according to data from a phase 2 HLHR130 trial.

Maintenance Rucaparib Shows Efficacy in Advanced Pancreatic Cancer Harboring BRCA1, BRCA2, or PALB2

May 20th 2021

The PARP inhibitor rucaparib has proven to be a safe and effective maintenance option for patients with platinum-sensitive, advanced pancreatic cancer that harbors pathogenic variants such as BRCA1, BRCA2, or PALB2.

SBRT Appears to Be Safe, Feasible in Oligometastatic Disease With Multiple Metastases

May 20th 2021

Stereotactic body radiotherapy can safely be used to treat patients with oligometastatic disease with 3 to 4 metastases or 2 metastases in close proximity to each other, according to results from the phase 1 NRG-BR001 trial.

Prophylactic Pelvic Radiotherapy Significantly Improves Biochemical Failure-Free Survival, DFS in High-Risk Prostate Cancer

May 20th 2021

Prophylactic whole-pelvic radiotherapy improved biochemical failure-free survival and disease-free survival vs prostate-only radiotherapy in patients with high-risk, locally advanced prostate cancer.

TIL-Based Therapies Possess Potential for Cure in Metastatic Melanoma, But Questions Remain

May 18th 2021

Tumor-infiltrating lymphocytes, a neoantigen-targeting therapy, has been shown to be a potentially curative treatment for patients with metastatic melanoma, and has led to clinical responses in this population even after failure with checkpoint inhibitors